Tsai Chia-Wen, Hsu Huai-Mei, Wang Yun-Chi, Chang Wen-Shin, Shih Liang-Chun, Sun Kuo-Ting, Hung Yi-Wen, Yang Yi-Chin, Gong Chi-Li, Bau DA-Tian
Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Anticancer Res. 2018 Dec;38(12):6821-6826. doi: 10.21873/anticanres.13055.
Metalloproteinase 2 (MMP2) is a multi-functional protein which has been shown to be up-regulated in patients with oral cancer, especially those with lymph node metastasis. However, the association of MMP2 genotype with oral cancer risk or metastatic behavior is unknown. This study aimed to evaluate the role of MMP2 promoter 1306 and -735 genotypes in the risk of oral cancer and metastasis.
In this case-control study, MMP2 promoter 1306 (rs243865) and -735 (rs2285053) genotypes and their interaction with consumption of areca, cigarettes, and alcohol in determining oral cancer risk were investigated among 788 patients with oral cancer and 956 gender-matched healthy controls. In addition, their role in oral cancer metastasis were also examined.
The distribution of CC, CT and TT for MMP2 promoter 1306 genotype was 79.0, 20.1 and 0.9% in the oral cancer group and 68.7, 29.2 and 2.1% in the non-cancer control group, respectively (p for trend=4.3E-6). The allelic frequency distributions showed that the variant T allele of MMP2 promoter 1306 conferred lower oral cancer susceptibility than the wild-type C allele (odds ratio=0.61, 95% confidence interval=0.50-0.75, p=1.1E-6). As for the MMP2 -735 genotypes, there was no differential distribution in genotypic or allelic frequencies. The variant CT and TT genotypes were also associated with lower metastasis rates within 5 years among the patients with oral cancer (odds ratio=0.34, 95% confidence interval=0.15-0.80, p=0.0102).
The CT and TT genotypes of MMP2 promoter 1306 may have a protective effect on oral cancer susceptibility and metastasis risk within 5 years for Taiwanese. They may serve as predictive markers for oral cancer in precise medical practice.
金属蛋白酶2(MMP2)是一种多功能蛋白,已证实在口腔癌患者中表达上调,尤其是那些有淋巴结转移的患者。然而,MMP2基因分型与口腔癌风险或转移行为之间的关联尚不清楚。本研究旨在评估MMP2启动子1306和-735基因分型在口腔癌风险和转移中的作用。
在这项病例对照研究中,对788例口腔癌患者和956例性别匹配的健康对照者,研究了MMP2启动子1306(rs243865)和-735(rs2285053)基因分型及其与槟榔、香烟和酒精消费在确定口腔癌风险中的相互作用。此外,还研究了它们在口腔癌转移中的作用。
MMP2启动子1306基因分型的CC、CT和TT分布在口腔癌组分别为79.0%、20.1%和0.9%,在非癌对照组分别为68.7%、29.2%和2.1%(趋势p=4.3E-6)。等位基因频率分布显示,MMP2启动子1306的变异T等位基因赋予的口腔癌易感性低于野生型C等位基因(优势比=0.61,95%置信区间=0.50-0.75,p=1.1E-6)。至于MMP2 -735基因分型,基因型或等位基因频率没有差异分布。变异的CT和TT基因型也与口腔癌患者5年内较低的转移率相关(优势比=0.34,95%置信区间=0.15-0.80,p=0.0102)。
MMP2启动子1306的CT和TT基因型可能对台湾人5年内的口腔癌易感性和转移风险具有保护作用。它们可作为精准医疗实践中口腔癌的预测标志物。